In a man with a rising prostate-specific antigen level and a clinically enlarged prostate, should the next step be a multiparametric magnetic resonance imaging or a transrectal ultrasound‑guided biopsy?

MRI Should Be Performed Before Biopsy in Biopsy-Naïve Men with Rising PSA

In a man with rising PSA and clinically enlarged prostate, multiparametric MRI (mpMRI) should be performed first, followed by MRI-targeted biopsy only if suspicious lesions are identified (PI-RADS ≥3), rather than proceeding directly to TRUS biopsy. 1

Rationale for MRI-First Pathway

The 2024 European Association of Urology guidelines explicitly recommend mpMRI as the preferred initial diagnostic step in biopsy-naïve men with suspected prostate cancer 1. This represents a fundamental shift from the historical TRUS-first approach.

Superior Detection of Clinically Significant Cancer

• mpMRI demonstrates pooled sensitivity of 0.91-0.95 for detecting clinically significant prostate cancer (csPCa, defined as ISUP grade ≥2), compared to only 48% sensitivity for standard TRUS biopsy 1, 2
• The PROMIS trial showed mpMRI detected 93% of clinically significant cancers versus 48% for TRUS biopsy, while being less specific (41% vs 96%) 2
• Head-to-head comparison in 626 biopsy-naïve men showed the MRI pathway detected equivalent rates of csPCa (25%) compared to TRUS (23%), but with 89% fewer biopsy cores required 3

Reduction in Unnecessary Biopsies

• The MRI-first pathway allows 27-49% of men to avoid biopsy entirely when mpMRI is negative (PI-RADS 1-2) 1, 3, 2
• Among men with negative mpMRI who avoided biopsy, only 3-4% had clinically significant cancer on follow-up, making this an acceptable miss rate 3
• This biopsy avoidance reduces complications including sepsis (reported in 5.9% of biopsied patients in PROMIS) 2

Dramatic Reduction in Overdiagnosis

• MRI-targeted biopsy reduces detection of clinically insignificant cancer by 57-89% compared to systematic TRUS biopsy 3, 2, 4
• TRUS biopsy detected insignificant cancer in 25% of men versus only 14% with the MRI pathway 3
• This reduction in overdiagnosis prevents unnecessary treatment and associated morbidity from interventions for indolent disease 1

Practical Implementation Algorithm

Step 1: Risk Stratification with PSA Density

• Calculate PSA density (PSA ÷ prostate volume from imaging or DRE estimation) 1
• Combine PSA-D with PI-RADS score using the risk-adapted matrix: men with PI-RADS 1-2 and PSA-D <0.10 ng/ml have very low risk and may avoid biopsy entirely 1

Step 2: Perform 1.5T or 3T mpMRI

• Use standardized PI-RADS v2.1 scoring system 1
• Ensure high-quality imaging with experienced radiologists to achieve the 49% negative MRI rate seen in optimal studies (versus 27-36% in less experienced centers) 3

Step 3: Biopsy Decision Based on MRI Findings

PI-RADS 1-2 (Negative):

• Avoid immediate biopsy in 49% of men 3
• Consider PSA surveillance with repeat MRI if PSA continues rising 1
• Accept 3-4% risk of missing csPCa, which is clinically acceptable given the 20% risk of detecting insignificant cancer with TRUS 3

PI-RADS 3 (Equivocal):

• Integrate with PSA-D: if PSA-D <0.15 ng/ml, consider surveillance; if ≥0.15 ng/ml, proceed to targeted biopsy 1
• Perform MRI-targeted biopsy with 2-4 cores per lesion 1

PI-RADS 4-5 (Suspicious):

• Perform MRI-targeted biopsy (in-bore or fusion technique) 1, 3
• Add 4 perilesional cores around the target, which improves csPCa detection by 7% 3
• Consider adding systematic sampling in select cases, though this increases insignificant cancer detection 3

Critical Caveats

When to Consider Direct TRUS Biopsy

• If mpMRI is unavailable or contraindicated (claustrophobia, metallic implants, renal dysfunction precluding contrast), proceed directly to systematic TRUS biopsy 1
• In men with very high clinical suspicion (PSA >50 ng/ml, malignant-feeling prostate on DRE, clinical stage T3-4), consider proceeding directly to biopsy or even staging studies before biopsy 1

Quality Considerations

• The superior outcomes with MRI-first depend on high-quality imaging and experienced interpretation 3
• Centers with less experienced radiologists may have higher rates of equivocal findings (15-28% vs 6% in high-quality studies), reducing the benefit 3

Limitations of MRI

• mpMRI has relatively low specificity (35-41%), meaning many men with positive MRI will have negative biopsies 1, 2
• Anterior and transition zone cancers are better detected by MRI, but some clinically significant cancers in other locations may be missed 5

Comparison with Historical TRUS-First Approach

The American College of Radiology 2017 guidelines, while acknowledging emerging MRI data, still listed TRUS biopsy as standard of care with MRI as an adjunct 1. However, the subsequent high-quality trials (PROMIS 2017, head-to-head comparison 2019) and updated EAU 2024 guidelines have definitively shifted the paradigm to MRI-first 1, 3, 2.

The evidence overwhelmingly supports that proceeding directly to TRUS biopsy without mpMRI is now suboptimal care for biopsy-naïve men, as it results in more unnecessary biopsies, higher detection of insignificant cancer, and paradoxically lower detection of clinically significant cancer 1, 3, 2.